SLATE-ASSET-MANAGEMENT
15.9.2022 20:01:38 CEST | Business Wire | Press release
Slate Asset Management (“Slate”), a global alternative investment platform targeting real assets, today announced a strategic partnership with Roswall Development Inc. (“Roswall”), a fully integrated Canadian renewable energy company based in Halifax, Nova Scotia, through the acquisition of a significant minority stake in the company.
Roswall is an experienced developer of renewable energy projects offering complete energy solutions for infrastructure, industries, and communities in partnership with private and public enterprises. Roswall’s full suite of services includes consulting, strategic planning, design-build installations, development, financing, and operations of renewables projects. The leadership team at Roswall has been active in the renewable energy industry for over 15 years, having successfully developed, constructed, and operated C$150 million of wind, solar, and retrofit projects across North America. Roswall was also awarded the first independent retail electricity licence in Nova Scotia in October 2021.
The partnership with Slate will help fund future renewables projects developed by Roswall, which has a significant and actionable pipeline of wind development opportunities that will support its retail operation by providing 100% clean electricity to its customers. Additionally, it has a growing turnkey business focused on commercial, institutional, and industrial markets. The Roswall team will also benefit from the global expertise, resources, and relationships of the broader Slate platform as it looks to scale its platform across Canada and North America.
“We believe that proven and scalable renewable energy solutions can meaningfully improve the resiliency of our cities and communities by reducing energy consumption, minimizing the environmental impacts of energy production, and increasing the reliability and efficiency of our energy sources,” said Christian Schmid, Managing Director and Global Head of Infrastructure at Slate. “Roswall’s experienced team has been on the front lines of the significant energy transition taking place globally over the past decade, working to broaden access to affordable, reliable, sustainable, and modern energy sources across North America. We look forward to partnering closely with the Roswall team on integrations across our own real estate portfolio and supporting their mission of continuing to accelerate the energy transition worldwide.”
Daniel Roscoe, Chief Executive Officer at Roswall, said: “The energy economy is changing at a dramatic pace. We have shown with our work in Nova Scotia and the Caribbean that locally produced renewable energy combined with energy retrofits can provide cost savings, emission reductions, and energy security. We are excited to find a likeminded partner in Slate, with the capacity and experience to grow our approach and accelerate energy transition and climate action here in Nova Scotia and abroad.”
Slate is an active investor in sustainable assets and technologies that advance the global energy transition and enable cities and communities to reach their carbon emission reduction goals. The firm recently hired Jeff Rodgers as Managing Director, North American Infrastructure to support the continued growth of Slate’s infrastructure platform globally, with a focus on uncovering investment opportunities tied to the global energy transition in the US and Canada.
About Slate Asset Management
Slate Asset Management is a global alternative investment platform targeting real assets. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of real estate and infrastructure investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities. Visit slateam.com to learn more.
About Roswall Development Inc.
Roswall Development Inc. is an experienced developer of renewable energy projects, encompassing all aspects from financing and construction to operation. We are focused on enabling regions, industries, and public institutions to become energy self-sufficient through development of renewable energy systems and energy efficiency retrofits. Roswall's team has over 15 years of experience with over $150M of wind, solar and retrofit projects successfully developed, constructed and operated. Active in both Canada and the Caribbean, Roswall is helping accelerate the energy transition by helping companies and institutions get to zero emissions cost effectively. Learn more at roswall.ca.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005149/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom